<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542337553714">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">16.11.2018 03:05:53 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.u13g4zm1lu87</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>What are the hours of work? &lt;a href=&quot;http://reflectiveteens.com/stmap_213a0.html?effexor.symmetrel.avana.cialis&quot;&gt;aloe cadabra canada&lt;/a&gt;  Teva also plans to focus on new therapeutic entities (NTEs),which could be new uses, formulations, delivery methods orcombinations of existing products. So far at least 13 have beenapproved for development this year and Teva expects some ofthese to be launched in the next few years.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
